“alzheimers-disease” Archives

in
Entry Author Date Location
What’s Hot in Seattle Biotech: Tech, Life Sciences Convergence & More 06/19/18 Seattle
Bio Roundup: Not-BIO Party Foul, CRISPR Drama, Sickle Cell Updates 06/15/18 National
Cellular Dynamics, Rockwell, WARF & More: This Week’s WI Watchlist 06/11/18 Wisconsin
Bio Roundup: Wrapping ASCO, Dreaming IPO, Rebooting Axovant & More 06/08/18 National
Biogen Makes Another Small Bet With Option Deal for TMS Stroke Drug 06/07/18 Boston
Biogen Pays $1B to Broaden Ionis Pact, Betting More on RNA Drugs 04/20/18 Boston
With Alzheimer’s Failure, vTv Fares No Better Than Old Partner Pfizer 04/09/18 Raleigh Durham
Alzheon Files for IPO to Fund Studies of Amyloid Alzheimer’s Drug 03/16/18 Boston
With $69M Deal, AbbVie Turns to Voyager for an Alzheimer’s Gene Therapy 02/20/18 Boston
With IPO, BioXcel Looks to Fund AI-Fueled Drug Discovery Work 02/14/18 New York
Axovant CEO Hung, COO McCourt Resign After Brain Drug’s Failures 02/12/18 National
Bio Roundup: #JPM18, Axovant’s Fall, CRISPR Caveat, Impact M&A & More 01/12/18 National
Axovant Neuro Drug Stumbles and Falls in Phase 2, Shares Drop 50% 01/08/18 National
Denali, Takeda Reach $155M Deal to Develop Alzheimer’s Drug & Others 01/05/18 San Francisco
Bio Roundup: Tax Cuts, Drug Approval Record, New Flagship Cash & More 12/22/17 National
Biogen, Eisai Alzheimer’s Drug Fails First Test But Study Continues 12/21/17 Boston
In Biggest Biotech IPO of 2017, Denali Raises $248M for Neuro Drugs 12/08/17 San Francisco
Bio Roundup: Trials to Watch, Mega Deals, Video Game Therapy & More 12/08/17 Boston
15 For ’18: Key Clinical Data to Watch For Next Year (Part 1) 12/04/17 National
VCs Put More Dollars Into Exosomes as Codiak Bio Lands $76M 11/29/17 Boston
IPO to Fuel Denali’s Drugs for Alzheimer’s, Other Brain Diseases 11/13/17 San Francisco
Bio Roundup: CBO’s Praise, Celgene’s Shock, Trump’s Opioid Plan & More 10/27/17 National
As Drugs Fail, Some Researchers Urge a Return to Alzheimer’s Roots 10/25/17 National
Bio Roundup: Graham-Cassidy, Axovant Fail, SpringWorks Launches & More 09/29/17 National
No Effect: Axovant Drug Is Latest Casualty in Alzheimer’s Battle 09/26/17 National
E-Scape Unveils $63M for Alzheimer’s, Parkinson’s Drug Research 07/12/17 San Francisco
Alzheimer’s Drug Pipeline Analysis: Have We Hit Peak Amyloid? 06/21/17 National
Will New Data Open “Bottlenecks” For Biogen’s Pricey Spine Drug? 04/26/17 Boston
Gates Foundation Leads $45.5M Round for Gerngross’s Biotech Arsanis 04/26/17 Boston
Phoenix Shops Its Cancer Drug as Potential Alzheimer’s Treatment 04/20/17 Texas
Page 2 of 5 « previous page · next page »